NZYM B Novozymes A/S Class B

Trading by management and close relations of management

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016

of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.

Please read the full announcement in PDF.

Attachment



EN
23/03/2026

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Resolutions from the Annual General Meeting 2026

Resolutions from the Annual General Meeting 2026 Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.25 (corresponding to approximately EUR 0.3) was disbursed on August 27, 2025Approval of the Remuneration Report for 2025 (advisory vote)Approval of the remuneration of membe...

March 23, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

March 23, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility

Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility COPENHAGEN, Denmark – March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge facility related to Novonesis’ purchase of the dsm firmenich’s part in the Feed Enzyme Alliance, closed in June 2025. The acquisition gives Novonesis full control of the alliance’s sales and distribution, strengthening the company’s position across the animal biosolutions value chain. Rainer Lehmann, CFO...

March 16, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis issues EUR 1.7 billion senior unsecured notes

Novonesis issues EUR 1.7 billion senior unsecured notes On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly established EUR 4 billion Euro Medium Term Note (EMTN) Programme, dated March 10, 2026. The Notes will be issued on March 19, 2026, and listed on the Luxembourg Stock Exchange. This inaugural issuance consists of three tranches with maturities ranging from 4 to 11 years and fixed interest rates ranging from 3.25% to 4.00%. ...

March 13, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

March 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch